Federal Register / Vol. 87, No. 112 / Friday, June 10, 2022 / Notices 35559 

Bethesda, MD 20892, (301) 867–5309, 

jiragedb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Skeletal Muscle and Exercise 

Physiology. 

Date: July 20, 2022. 

Time: 1:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Carmen Bertoni, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 805B, 

Bethesda, MD 20892, (301) 867–5309, 

bertonic2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Biomedical Data Repositories and 

Knowledgebases. 

Date: July 21, 2022. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Noffisat Oki, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (240) 627–3648, noffisat.oki@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 6, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12484 Filed 6–9–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Dawn Taylor-Mulneix at 301–767–5189, 

or dawn.taylor-mulneix@nih.gov. 

Licensing information may be obtained 

by communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852: tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Human Monoclonal Antibodies That 

Broadly Target Coronaviruses 

Description of Technology 

The family of coronaviruses cause 

upper respiratory tract disease in 

humans and have caused three major 

disease outbreaks in recent history: the 

2003 SARS outbreak, the 2012 MERS 

outbreak, and the current SARS–CoV–2 

pandemic. There is an urgent need for 

strategies that broadly target 

coronaviruses, both to deal with new 

SARS–CoV–2 variants and future 

coronavirus outbreaks. 

Scientists at NIAID have developed 

several novel human monoclonal 

antibodies that bind to conserved parts 

of the SARS–CoV–2 spike protein. 

These antibodies can neutralize SARS– 

CoV–2 variants of concern including 

Omicron BA.1 and BA.2, as well as 

neutralize at least one other 

betacoronavirus. Further, these 

antibodies limit disease in animal 

models. Broadly reactive antibodies 

against coronaviruses are useful tools to 

identify conserved sites on the 

coronavirus spike protein, which could 

be investigated for the development of 

broad coronavirus vaccines that aim to 

prevent future pandemics. Potent 

neutralizers that target these sites could 

also be useful for prevention of disease 

caused by diverse coronaviruses, 

including those that may emerge in the 

future. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Prophylactic usage against SARS– 

CoV–2 and/or other betacoronaviruses 

in normal or high-risk populations. 

• Therapeutic treatment, alone or in 

combination, in patients with SARS– 

CoV–2 and/or other betacoronaviruses 

infections. 

• Assay development for 

surveillance, diagnostic, and prevention 

measures. 

Competitive Advantages 

• Antibodies can neutralize SARS– 

CoV–2 variants, including Omicron 

BA.1 and BA.2. 

• Antibodies can broadly target and 

neutralize betacoronaviruses. 

Development Stage 

• Pre-Clinical. 

Inventors: Joshua Tan, Ph.D., 

Cherrelle Dacon, Ph.D., both of NIAID. 

Publications: Dacon, C., et al. 

‘‘Broadly neutralizing antibodies target 

the coronavirus fusion peptide’’ bioRxiv 

2022.04.11.48789. Doi: https://doi.org/ 

10.1101/2022.04.11.48789 (This article 

is a preprint and has not been certified 

by peer review) 

Intellectual Property: HHS Reference 

No. E–047–2022–0–EIR–00 U.S. Patent 

Application No. 63/308,898, filed on 

February 10, 2022. 

Licensing Contact: To license this 

technology, please contact Dawn TaylorMulneix at 301–767–5189, or 

dawn.taylor-mulneix@nih.gov, and 

reference E–047–2022. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Areas of 

specific interest include (a) testing 

developability of these antibodies (e.g., 

biophysical characteristics, crossreactivity, pharmacokinetics, toxicity), 

(b) pre-clinical model assessment, and 

(c) human clinical trials. For 

collaboration opportunities, please 

contact Dawn Taylor-Mulneix at 301– 

767–5189, or dawn.taylor-mulneix@

nih.gov. 

Dated: June 3, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–12485 Filed 6–9–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 


jspears on DSK121TN23PROD with NOTICES1